As of Q3'25, Eli Lilly's EV/Sales ratio stands at 47.22, reflecting a notable decrease from its recent peak of 87.38 in Q1'24. This latest figure indicates a continued downward adjustment in valuation relative to sales over the most recent quarters. From Q1'23 to Q1'24, the EV/Sales ratio experienced significant growth, rising from 55.44 to a high of 87.38, suggesting heightened investor optimism or premium valuation during that period. However, starting in Q2'24, the trend reversed, with the ratio declining steadily to 41.33 by Q2'25 before a slight rebound in Q3'25. This pattern highlights a period of volatility, with a sharp run-up followed by a substantial correction, indicating shifting market sentiment or changes in revenue expectations over the observed timeframe.